MICHAEL WILL: Open Payments
NPI 1073876090 · PALM DESERT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,101 in 55 payments from 18 companies in 2025. Trend: 2023 $1,513 · 2024 $1,245 · 2025 $1,101
Food & beverage: $1,101
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $281 |
| Lilly USA, LLC | 8 | $152 |
| GlaxoSmithKline, LLC. | 5 | $91 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $73 |
| Amgen Inc. | 4 | $69 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $61 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $56 |
| Almatica Pharma LLC | 3 | $55 |
| Novo Nordisk Inc | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
Products named: AIRSUPRA, MOUNJARO, TRELEGY ELLIPTA, FARXIGA, JARDIANCE, XIFAXAN, Kerendia, LOREEV XR.
Industry payments across CA — which companies pay providers there.
